Identification of Core Targets: Five critical anti-GC targets (CDK1, CCNA2, TOP2A, CHEK1, and PLK1) were identified, with a focus on their roles in cell cycle regulation and chemotherapy resistance, providing mechanistic insights into Diosgenin’s anti-tumor effects. This evidence concerns the gene CHEK1 and neoplasm.